JP2021523125A5 - - Google Patents

Info

Publication number
JP2021523125A5
JP2021523125A5 JP2020561786A JP2020561786A JP2021523125A5 JP 2021523125 A5 JP2021523125 A5 JP 2021523125A5 JP 2020561786 A JP2020561786 A JP 2020561786A JP 2020561786 A JP2020561786 A JP 2020561786A JP 2021523125 A5 JP2021523125 A5 JP 2021523125A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
therapeutic pharmaceutical
receptor agonist
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523125A (ja
JP7458032B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030652 external-priority patent/WO2019213558A1/en
Publication of JP2021523125A publication Critical patent/JP2021523125A/ja
Publication of JP2021523125A5 publication Critical patent/JP2021523125A5/ja
Application granted granted Critical
Publication of JP7458032B2 publication Critical patent/JP7458032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561786A 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Active JP7458032B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666675P 2018-05-03 2018-05-03
US62/666,675 2018-05-03
IN201841019588 2018-05-25
IN201841019588 2018-05-25
PCT/US2019/030652 WO2019213558A1 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Publications (3)

Publication Number Publication Date
JP2021523125A JP2021523125A (ja) 2021-09-02
JP2021523125A5 true JP2021523125A5 (cg-RX-API-DMAC7.html) 2022-05-13
JP7458032B2 JP7458032B2 (ja) 2024-03-29

Family

ID=68386694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561786A Active JP7458032B2 (ja) 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Country Status (9)

Country Link
US (1) US12629406B2 (cg-RX-API-DMAC7.html)
EP (2) EP3813942B1 (cg-RX-API-DMAC7.html)
JP (1) JP7458032B2 (cg-RX-API-DMAC7.html)
CN (1) CN112469474A (cg-RX-API-DMAC7.html)
AU (1) AU2019262612B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022395A2 (cg-RX-API-DMAC7.html)
ES (1) ES2978951T3 (cg-RX-API-DMAC7.html)
PL (1) PL3813942T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019213558A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
WO2022240964A1 (en) * 2021-05-11 2022-11-17 Pharmazz, Inc. Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19)
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
IN202411028038A (cg-RX-API-DMAC7.html) * 2024-04-04 2025-05-23

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ 1―m―トリル―4―(B―2―キノリエチル)―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
EP0126327A1 (en) 1983-04-26 1984-11-28 Frank J. Macri Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
JPH0597891A (ja) * 1991-04-24 1993-04-20 Banyu Pharmaceut Co Ltd 血管弛緩ペプチド類
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CN1729012B (zh) 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20050009847A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
JP4976412B2 (ja) * 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
JP2009530407A (ja) 2006-03-23 2009-08-27 アミリン・ファーマシューティカルズ,インコーポレイテッド 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
BRPI0809171A2 (pt) 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
CA2683857A1 (en) 2007-04-10 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted deuterium enriched thiophenes for the treatment of hypertension
PL2182977T3 (pl) 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
PL2424529T3 (pl) * 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
WO2011159854A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
US20150250782A1 (en) 2012-08-31 2015-09-10 Pharmazz, Inc. Methods and Compositions for Hypotensive Resuscitation
EP3019242B1 (en) * 2013-07-08 2020-08-19 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
CN112469474A (zh) 2018-05-03 2021-03-09 美国中西部大学 出血和centhaquin引起的复苏后内皮素受体的变化
JP2025149692A (ja) 2024-03-26 2025-10-08 ローム株式会社 無線通信回路
JP2026006612A (ja) 2024-06-28 2026-01-16 多摩川精機株式会社 温度検出体固定用溝付き絶縁キャップ、回転電機の温度検出体固定構造、温度検出体固定済み回転電機、回転電機の温度検出体固定方法、および回転電機製造装置

Similar Documents

Publication Publication Date Title
Wilson Clinical pharmacokinetics of teicoplanin
ES3043583T3 (en) Dapagliflozin for use in methods of treating chronic kidney disease
JP2019517542A5 (cg-RX-API-DMAC7.html)
KR100347631B1 (ko) 해열진통배합제
HUP0104085A2 (hu) Vazopresszin antagonisták alkalmazása pulmonáris hipertenzió kezelésére szolgáló gyógyszerkészítmények előállítására
JP2021523125A (ja) 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化
US20260102472A1 (en) Semaglutide in medical therapy
Bridgeman et al. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy
Seaton et al. Possible potentiation of warfarin by fluconazole
JP2004538319A5 (cg-RX-API-DMAC7.html)
US20090285909A1 (en) Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
JP2021531297A5 (cg-RX-API-DMAC7.html)
JP2002326936A5 (cg-RX-API-DMAC7.html)
CN102091052B (zh) 双环醇双层渗透泵控释片剂及其制备方法
HU222888B1 (hu) Anilid vegyületek alkalmazása I típusú allergiás betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
Munger New agents for managing hyponatremia in hospitalized patients
KR101210831B1 (ko) 폴리에틸렌글리콜과 비타민 씨를 함유하는 장관 하제 조성물
JP2002505678A (ja) 腫瘍組織を選択的に制御するための、相乗効果を有する組成物
JPS58140017A (ja) 心不全治療剤
US4798811A (en) Combination preparation
Schernthaner et al. Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
WO2017037737A1 (en) Parenteral formulations of levosimendan
WO2007129618A1 (ja) 好中球の活性化および遊走因子の抑制剤およびその利用
JP2008533109A (ja) 利尿を促進するための複合治療
JP2023538984A5 (cg-RX-API-DMAC7.html)